quantisnow
FeedTopReportsPricing
⌘K
Live feed
18:30:00·69d
PRRelease
Psyence Biomedical Ltd. logo

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

PBM· Psyence Biomedical Ltd.
Health Care
Original source

Companies

  • PBM
    Psyence Biomedical Ltd.
    Health Care

Related

  • SEC18h
    SEC Form 6-K filed by Psyence Biomedical Ltd.
  • PR1d
    Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
  • SEC4d
    SEC Form 6-K filed by Psyence Biomedical Ltd.
  • PR4d
    Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
  • SEC6d
    SEC Form 6-K filed by Psyence Biomedical Ltd.
  • PR7d
    Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
  • PR16d
    Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
  • PR44d
    Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022